A new animal model of systemic lupus erythematosus (lupus) could be useful for understanding the disparity of the disorder, which is vastly more common in women than men.

Versant Ventures is committing $50 million in series A funding to Cimeio Therapeutics Inc., which aims to bring new possibilities in terms of disease targeting and safety to bear on a wide range of cell therapy applications, including hematopoietic stem cell transplantation (HSCT) and adoptive cell transfer.